非小细胞肺癌（NSCLC）的化疗宝典

老马 · 发表于 2014-1-5 12:51:06

Supplements—for better or worse?
Chemotherapy-induced peripheral neuropathy is a very common and debilitating adverse effect of cancer therapy, which can often lead to treatment discontinuation. There are no good treatments or ways to prevent this adverse effect. However, preclinical studies and a phase II trial showed that the natural compound acetyl-L-carnitine (ALC) has efficacy, with improvements noted in some
patients. This finding prompted Dawn Hershman and colleagues to conduct a prospective, randomized, placebo-controlled trial in women undergoing taxane-based adjuvant therapy for early
stage breast cancer.
In total, 409 patients were randomly assigned to receive ALC or placebo. The primary outcome of the trial was patient-reported symptoms of peripheral neuropathy. Unfortunately, as Hershman
summarizes, the results of the trial were negative. “Not only did we not find a protective effect of ALC at 12 weeks, we found that by 24 weeks there was a statistically significant worsening of
peripheral neuropathy in the patients on trials that were randomized to the ALC supplement.”
To the authors’ knowledge, this is the first study to show a detrimental effect of a supplement on the development of taxane-related peripheral neuropathy. As the use of complementary medicine is widespread, the study researchers caution that patients should be discouraged from using ALC
and other nutritional supplements that do not have proven efficacy. Hershman comments on future plans for this area: “some studies are ongoing to see if ALC is more beneficial for treatment as opposed to prevention. We will investigate other approaches for treating and preventing
this terrible side effect.”
Lisa Hutchinson
Original article Hershman, D. L. et al. Randomized double-
blind placebo-controlled trial of acetyl-l-carnitine for
the prevention of taxane-induced neuropathy in women
undergoing adjuvant breast cancer therapy. J. Clin. Oncol.
doi:10.1200/JCO.2012.44.8738